NCT00929669 · OUTCOME

Number of Participants With Change in Serum FSH Concentration (mIU/mL) in Patients Who Have Gonadotroph Adenomas Treated With Pasireotide.

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas · Source last updated 2017-11-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: number of participants
Interval / dispersion: Not reported
Time frame: 12 months

What was measured

Serum FSH (mIU/mL) will be measured at baseline and then monthly for the 12 months of the study to determine if serum FSH concentrations decrease by 20%.

Groups in this outcome

Pasireotide LAR

80 mg IM once monthly

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Pasireotide LAR	1

Reported measurements

Source class 1

Values in number of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Pasireotide LAR	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
1
units
Participants

description

Serum FSH (mIU/mL) will be measured at baseline and then monthly for the 12 months of the study to determine if serum FSH concentrations decrease by 20%.

groups

description
80 mg IM once monthly
id
OG000
title
Pasireotide LAR

param Type

NUMBER

reporting Status

POSTED

time Frame

12 months

title

Number of Participants With Change in Serum FSH Concentration (mIU/mL) in Patients Who Have Gonadotroph Adenomas Treated With Pasireotide.

type

SECONDARY

unit Of Measure

number of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice